加载中
NASDAQHealthcareBiotechnology
最新数据
US$14.56
−US$0.06 · -0.41%
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
收盘时
US$14.56
−US$0.06 · -0.41%
盘后
US$14.57
+US$0.01 · +0.07%
10月12日 19:54 ET
盘中时间采用ET。市场数据可能有所延迟。
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
日内区间
当前US$14.56
52周区间
当前US$14.56
盘中时间采用ET。市场数据可能有所延迟。
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
日内区间
当前US$14.56
52周区间
当前US$14.56
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 2.64亿 USD | 1.64亿 USD | 118.9万 USD | — | — |
| 销货成本 | 1.73亿 USD | 1.24亿 USD | 1075.5万 USD | — | — |
| 毛利 | 9031.8万 USD | 4007.5万 USD | −956.6万 USD | — | — |
| 研究与开发 | 3亿 USD | 2.82亿 USD | 3.44亿 USD | 2.95亿 USD | 2.59亿 USD |
| 销售、一般及管理费用 | 1.52亿 USD | 1.53亿 USD | 1.07亿 USD | 1.04亿 USD | 8366.4万 USD |
| 营业费用 | 4.89亿 USD | 4.35亿 USD | 4.51亿 USD | 3.99亿 USD | 3.43亿 USD |
| 利息收入 | 1030.7万 USD | 2027.3万 USD | 1304.3万 USD | 298.5万 USD | 45.1万 USD |
| 利息支出 | — | — | — | 298.5万 USD | — |
| 折旧和摊销 | 4732.4万 USD | 4360.6万 USD | 3312.7万 USD | 2113.5万 USD | 1398万 USD |
| 营业利润 | −3.98亿 USD | −3.95亿 USD | −4.61亿 USD | −3.99亿 USD | −3.43亿 USD |
| 净利润 | −3.91亿 USD | −3.72亿 USD | −4.44亿 USD | −3.96亿 USD | −3.42亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$13.11
下跌空间 9.96%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2013年9月26日 | 1:100 | — | — |
股票拆分 | 2010年5月26日 | 23,999:1,000 | — | — |
已生效 2013年9月26日
1:100
已生效 2010年5月26日
23,999:1,000
报告持有此股票敞口的交易所交易基金。
State Street SPDR S&P Biotech ETFXBI1.62亿1.64%103.03亿 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM1.52亿0.19%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Morningstar Total Stock Market ETFVTI1.1亿0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Biotechnology ETFIBB4465.7万0.41%108.2亿 USD0.44%US$204.26-1.08%
Vanguard Morningstar Small-Cap ETFVB3984.98万0.02%1853亿 USD0.03%US$288.16-0.46%
Vanguard Extended Market ETFVXF3564.41万0.04%954亿 USD0.05%US$233.52-0.63%
Dimensional - US Small Cap ETFDFAS3115.79万0.09%338.69亿 USD0.31%US$78.17-0.23%
Schwab U.S. Small-Cap ETFSCHA3046.87万0.14%218.24亿 USD0.03%US$32.66-0.40%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBVanguard Morningstar Small-Cap ETFVBVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
